Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPRIT
2024-519540-32-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in post-COVID syndrome comparing Fluvoxamine with Placebo (2 arms). Primary endpoint: Fatigue severity (CIS-20R fatigue score) at week 12. Planned start Nov 2025; status: authorised.
02
Drugs
fluvoxamine
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2024-519540-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519540-32-00.